While loss of MITF at transcriptional level has recently been described as a marker of resistance to BRAF/MEK targeted therapy (1, 14), we also demonstrate in an independent melanoma cohort by immunostaining that loss of MITF at protein level is an inferior prognostic factor in stage III metastatic melanoma. Here, MAP2K7 is linked to metastatic melanoma.